冠脉内注射腺苷减少急性心肌梗死直接PTCA术中无再流的发生(英文)  

Intracoronary adenosine decreases the incidence of no reflow during percutaneous intervention in patients with acute myocardial infarction

作　　者：陈绍良[1] 袁争白[2] 叶飞[1] 方五旺[1] 宋杰[1] 查铭凡[1] 陈怀沁[3] Tamari 

机构地区：[1]南京市第一医院,南京210006 [2]淮北矿工总医院 [3]新加坡国立大学医院 [4]以色列心血管病中心

出　　处：《中国临床药理学与治疗学》2001年第4期295-300,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的　探讨冠状动脉内注射腺苷对急性心肌梗死急诊直接PTCA术中无再流现象发生的影响。方法79例急性心肌梗死患者被随机分配到腺苷组 (5 1例 )和非腺苷组 (2 8例 ) ,腺苷给药方法为在每次球囊扩张前及其后冠状动脉内弹丸式注射 2 4～4 8μg。结果　非腺苷组有 8例出现无血流(2 8.6 %) ,腺苷组有 3例出现无血流 (5 .9%)。注射腺苷患者未见明显合并症。结论　对于急性心肌梗死患者 ,急诊PTCA术中冠状动脉内注射腺苷安全有效 ,无再流发生率显著降低 ,因此对改善患者预后具有极为重要的意义。Aim To investigate the role of intracoronary adenosine for the prevention of no reflow. Methods The procedural outcomes of 79 patients who undertook percutaneous intervention in the setting of acute myocardial infarction was studied. Twenty-eight patients did not received intracoronary adenosine ,and fifty-one received intracoronary adenosine bolluses (24- 48 μg before and after each balloon inflation). Results Eight patients who were not given adenosine experienced no reflow ( 28.6%) and high in-hospital death rate, three of fifty-one patients ( 5.9%) in the adenosine group experienced no reflow. No untoward complications were noted during adenosine infusion. Conclusion Intracoronary adenosine bolus administration during percutaneous intervention in the patients with acute myocardial infarction is easy and safe and may significantly lessen the incidence of no reflow and may improve the outcome of this procedure.

关 键 词：急性心肌梗死 腺苷 经皮冠状动脉腔内成形术 无再流现象 AMI 

分 类 号：R654.2[医药卫生—外科学]